UK Wilson's Disease Drugs Market Report 2023 to 2030

UK Wilson's Disease Drugs Market Analysis

$ 3999

UK Wilson?s Disease Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Wilson?s Disease Drugs is growing rapidly as a result of rising prevalence of the disease, advancements in diagnostic techniques , increase in awareness about the disease due to patient advocacy programmes , support and incentives from regulatory authorities like incentives and orphan drug designations and increasing investment in research and development activities. Amneal Pharmaceuticals, Meda Pharmaceuticals, Teva Pharmaceuticals Industries Ltd. , Taj Pharmaceutical Limited, Ipsen Pharma, TSUMURA & CO., Mylan pharmaceuticals are the key global market players in wilson?s disease drugs market.

ID: IN10GBRD114 CATEGORY: Rare Diseases GEOGRAPHY: UK AUTHOR: Sakshi Mantri

Buy Now

UK Wilson's Disease Drugs Market Analysis Summary

UK Wilson's Disease Drugs Market is valued at around $16.1 Mn in 2022 and is projected to reach $18.28 Mn by 2030, exhibiting a CAGR of 1.6% during the forecast period 2023-2030.

Wilson's disease is a rare genetic disorder which occurs due to the accumulation of copper in different body organs such as the liver, brain, eyes and other vital organs. The disease takes place due to a mutation in the ATP7B gene. Hepatic indications like reduced biliary excretion of copper result in excessive accumulation of copper in the liver. Symptoms of this disease are tiredness, hepatitis with elevated levels of gamma-glutamyl transpeptidase, alanine aminotransferase and aspartate aminotransferase enzymes. Damage to neurons, tremors and parkinsonism also occur in this disease. Wilson's illness requires lifelong treatment that aims to reduce copper levels to safe levels, stop the disease from progressing, and try to reverse any signs and symptoms brought on by copper accumulation in the body. Treatment can be broken down into three stages: the initial treatment of symptomatic patients, the subsequent maintenance therapy once the copper level in the affected tissues has decreased, and finally the initial use of maintenance therapy in asymptomatic patients. Copper Chelators such as D-penicillamine, Trientine hydrochloride and Tetrathiomolybdate are one treatment option. Zinc Salts like zinc acetate and zinc gluconate can also be done. Severe cases require liver transplantation. Copper chelators and zinc salts are the most commonly used and are expected to drive the market in future. Their combination is also used. Amneal Pharmaceuticals, Meda Pharmaceuticals, Teva Pharmaceuticals Industries Ltd., Taj Pharmaceutical Limited, Ipsen Pharma, TSUMURA & CO., and Mylan Pharmaceuticals are the key global market players in Wilson’s disease drugs market.

Market Dynamics

Market Drivers

Increase in the prevalence of Wilson disease, rise in adoption of early diagnosis, increase in investment by players in R&D and presence of robust pipeline candidates, rise in expenditure on the development of healthcare infrastructure, increase in public awareness about the disease and shift towards gene therapy. All these factors act as market growth drivers.

Market Restraints

Lack of awareness about the disease, lack of diagnosis facility associated with Wilson disease treatment and high treatment cost act as market growth restraints in Wilson’s disease drugs market.

Key players

Genzyme Alexion Pharmaceuticals CSL Behring Octapharma Grifols Kedrion Biopharma Baxter International GlycoMimetics Vir Biotechnology Intercept Pharmaceuticals

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For UK Wilson’s Disease Drugs market

By treatment

Medication
D-Penicillamine
Trientine
Tetrathiomolybdate
Surgery

By diagnosis

Blood and Urine Test
Eye Exam
Biopsy
Genetic Testing

By Route of Administration

Oral
Parenteral
Others

By End-Users

Hospitals
Homecare
Specialty Clinics
Others

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.